“…Despite the similar composition, nanovaccines can be categorized into several different groups depending on material features, including lipid, polymer, inorganic and biomimetic nanovaccines. − Polymers, in particular, could be a superior option owing to their low systemic toxicity, ease of synthesis, flexible in surface modification, and tailored design. − Notably, polymers have recently been studied as adjuvant and antigen delivery carriers and offer the potential to codeliver antigens and adjuvants to improve effectiveness and reduce dose. , The U.S. Food and Drug Administration (FDA) has authorized a list of polymeric carrier materials for their exceptional safety and biocompatibility, contributing to the creation of polymeric nanovaccine formulations, including poly(lactic-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(methyl methacrylate) (PMMA), poly(caprolactone) (PCL), chitosan, etc. − Polymeric nanovaccines are being studied not only for cancer therapy but also for antiviral immunotherapy and antimicrobial medications . For instance, Lin et al developed a safe and efficient prophylactic against the Middle East respiratory syndrome coronavirus by employing a synthetic biodegradable PLGA polymer to distribute subunit viral antigens, STING (stimulator of interferon genes) agonists, and adjuvants in a virus-like fashion. , In addition, Brucella abortus ( B. abortus ), a selective pathogen that causes brucellosis, may infect humans by direct contact with or consumption of animal products by unintentional hosts .…”